Aslan Pharmaceuticals

🇸🇬Singapore

Country: 🇸🇬Singapore

Ownership: -

Employees: 35

Market Cap: $1.6M

Website

Introduction: ASLAN Pharmaceuticals Ltd is a clinical-stage immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. The company is evaluating ASLAN004, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, a potent oral inhibitor of DHODH, which is being developed for autoimmune disease. The Company’s major business is research and development and operates only in one single segment.

Clinical Trials

Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer

Phase 2

Completed

Conditions: Biliary Tract Cancer

Interventions: Drug: Capecitabine
Drug: Varlitinib
Drug: Placebo (for Varlitinib)

First Posted Date: 2017-03-28

Last Posted Date: 2021-08-03

Lead Sponsor: ASLAN Pharmaceuticals

Target Recruit Count: 151

Registration Number: NCT03093870

Locations: 🇺🇸
Karmanos Cancer Institute/Wayne State University, Detroit, Michigan, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇯🇵
There are 7 sites in different cities in Japan, Chiba, Japan

and more 18 locations

A Study of Varlitinib in Japanese Subjects With Advanced or Metastatic Solid Tumours

Phase 1

Completed

Conditions: Advanced or Metastatic Biliary Tract Cancer
Advanced or Metastatic Solid Tumors

Interventions: Drug: varlitinib
Drug: capecitabine

First Posted Date: 2017-03-17

Last Posted Date: 2018-06-28

Lead Sponsor: ASLAN Pharmaceuticals

Target Recruit Count: 24

Registration Number: NCT03082053

Locations: 🇯🇵
ASLAN Selected sites, Tokyo, Japan

Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or Metastatic BTC

Phase 1

Terminated

Conditions: Biliary Tract Cancer

Interventions: Drug: Varlitinib
Drug: Cisplatin
Drug: Gemcitabine

First Posted Date: 2016-12-14

Last Posted Date: 2021-01-14

Lead Sponsor: ASLAN Pharmaceuticals

Target Recruit Count: 204

Registration Number: NCT02992340

Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-FU or Cisplatin and Capecitabine

Phase 1

Completed

Conditions: Solid Tumor

Interventions: Drug: ASLAN001
Drug: cisplatin + 5-fluorouracil (or+ Leucovorin)
Drug: cisplatin + capecitabine

First Posted Date: 2016-01-07

Last Posted Date: 2018-10-25

Lead Sponsor: ASLAN Pharmaceuticals

Target Recruit Count: 31

Registration Number: NCT02648425

Locations: 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
🇨🇳
Taipei Veterans General Hospital, Taipei, Taiwan
🇭🇰
Queen Mary Hospital, Hong Kong, Hong Kong